194 related articles for article (PubMed ID: 30642555)
1. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN
Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Krausz T; Borczuk A; Cagle PT; Chirieac LR; Churg A; Galateau-Salle F; Gibbs AR; Gown AM; Hammar SP; Litzky LA; Roggli VL; Travis WD; Wick MR
Arch Pathol Lab Med; 2009 Aug; 133(8):1317-31. PubMed ID: 19653732
[TBL] [Abstract][Full Text] [Related]
3. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P; Martorana F; Manzella L; Stella S
Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in malignant pleural mesothelioma.
Davidson B
Hum Pathol; 2015 Jun; 46(6):789-804. PubMed ID: 25824607
[TBL] [Abstract][Full Text] [Related]
6. Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
Wu L; Dell'Anno I; Lapidot M; Sekido Y; Chan ML; Kohno M; Serre-Beinier V; Felley-Bosco E; de Perrot M
Lung Cancer; 2019 Jan; 127():138-145. PubMed ID: 30642542
[TBL] [Abstract][Full Text] [Related]
7. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
8. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
10. What's new in mesothelioma.
Ascoli V; Murer B; Nottegar A; Luchini C; Carella R; Calabrese F; Lunardi F; Cozzi I; Righi L
Pathologica; 2018 Mar; 110(1):12-28. PubMed ID: 30259910
[TBL] [Abstract][Full Text] [Related]
11. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
12. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
13. MUC1 has prognostic significance in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Int J Biol Markers; 2013 Sep; 28(3):303-12. PubMed ID: 23828409
[TBL] [Abstract][Full Text] [Related]
14. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR
Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
17. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
18. Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Armato SG; Francis RJ; Katz SI; Ak G; Opitz I; Gudmundsson E; Blyth KG; Gupta A
Lung Cancer; 2019 Apr; 130():108-114. PubMed ID: 30885330
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
Liu H; Wu L; Ji K; Wang W
Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]